注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Tenax Therapeutics Inc是一家专业制药公司。该公司专注于识别和开发治疗方法,以解决医疗需求高度未满足的心肺疾病。该公司的产品包括TNX-103(口服左西孟旦)和TNX-201(口服肠溶伊马替尼)。该公司的主导产品左西孟旦是一种钙增敏剂/K-ATP激活剂,开发用于急性失代偿性心力衰竭住院患者的静脉注射。TNX-201用于治疗肺动脉高压(PAH),PAH是一种致命的孤儿疾病。该公司已经完成了左西孟旦在北美的II期临床试验,该试验用于治疗射血分数保持不变的心力衰竭合并肺动脉高压患者。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Daniel Burkhoff | - | 2018 | Member of PH-Left Heart Disease Scientific Advisory Board |
Sanjiv Shah | - | 2018 | Member of PH-Left Heart Disease Scientific Advisory Board |
Bradley Maron | - | - | Member of PAH Scientific Advisory Board |
Christopher T. Giordano | 49 | 2021 | CEO, President & Director |
Anna R. Hemnes | - | - | Member of PAH Scientific Advisory Board |
Declan Doogan | 72 | 2021 | Independent Director |
Gerald T. Proehl | 65 | 2014 | Independent Chairman |
Barry Borlaug | - | 2020 | Member of PH-Left Heart Disease Scientific Advisory Board |
Stuart Rich | 74 | 2018 | Chief Medical Officer & Director |
Robert P. Frantz | - | - | Member of PAH Scientific Advisory Board |
Michael Harvey Davidson | 68 | 2021 | Independent Director |
Robyn M. Hunter | 62 | 2022 | Independent Director |
June S. Almenoff | 67 | 2021 | Independent Director |
Javed Butler | - | 2023 | Member of PH-Left Heart Disease Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核